Bio-Rad Laboratories, Inc. (BIO) Gross Margin: 51.87%
Is Bio-Rad Laboratories, Inc.’s gross margin high or low?
Bio-Rad Laboratories, Inc.'s gross margin of 51.87% is in line with its 5-year average of 54.60%, near the low end of its 5-year range (51.87%–56.48%).
As of Sunday, June 14, 2026. 1.89% below its 12-month average of 52.87%.
BIO Gross Margin Chart
BIO Average Gross Margin Chart
BIO Current vs Average Gross Margin Chart
BIO Gross Margin Metrics
GROSS MARGIN
51.87%
GROSS MARGIN AVG TTM
52.87%
GROSS MARGIN AVG 3Y
53.77%
GROSS MARGIN AVG 5Y
54.60%
GROSS MARGIN AVG 10Y
54.64%
GROSS MARGIN AVG 15Y
55.00%
GROSS MARGIN AVG 20Y
55.02%
CURRENT VS TTM AVG
-1.89%
CURRENT VS 3Y AVG
-3.54%
CURRENT VS 5Y AVG
-5.01%
CURRENT VS 10Y AVG
-5.06%
CURRENT VS 15Y AVG
-5.69%
CURRENT VS 20Y AVG
-5.73%
BIO Competitors' Gross Margin
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Bio-Rad Laboratories, Inc. (BIO) | $7.73B | 51.87% | 52.87% | 53.77% | 54.60% |
| Tempus AI, Inc. (TEM)vs › | $8.35B | 69.55% | 62.30% | 54.75% | 44.45% |
| Charles River Laboratories International, Inc. (CRL)vs › | $9.03B | 31.86% | 31.70% | 34.15% | 35.17% |
| Hims & Hers Health, Inc. (HIMS)vs › | $5.98B | 67.64% | 76.65% | 78.21% | 76.94% |
| Walgreens Boots Alliance, Inc. (WBA)vs › | $10.37B | 17.13% | 18.71% | 19.98% | 20.79% |
| Baxter International Inc. (BAX)vs › | $10.77B | 30.11% | 33.76% | 35.72% | 36.84% |
| Align Technology, Inc. (ALGN)vs › | $12.52B | 67.68% | 69.16% | 69.73% | 70.75% |
| The Cooper Companies, Inc. (COO)vs › | $13.24B | 64.37% | 63.66% | 64.40% | 64.61% |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $2.02B | 48.93% | 50.81% | 52.12% | 52.25% |
| Solventum Corporation (SOLV)vs › | $13.66B | 53.67% | 54.56% | 56.03% | 57.27% |
Gross Margin Analysis
Gross Margin
51.9%
(Revenue - COGS) / Revenue
Bio-Rad Laboratories, Inc. Gross Margin Formula & Definition
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Bio-Rad Laboratories, Inc. Gross Margin FAQ
- What is the gross margin for Bio-Rad Laboratories, Inc. (BIO)?
- The gross margin for BIO stock is 51.87%.
- Is Bio-Rad Laboratories, Inc.'s gross margin high or low?
- Bio-Rad Laboratories, Inc.'s gross margin of 51.87% is in line with its 5-year average of 54.60%, near the low end of its 5-year range (51.87%–56.48%).
- What is the TTM average gross margin for Bio-Rad Laboratories, Inc. (BIO)?
- The TTM average gross margin for BIO stock is 52.87%.
- What is the 3Y average gross margin for Bio-Rad Laboratories, Inc. (BIO)?
- The 3Y average gross margin for BIO stock is 53.77%.
- What is the 5Y average gross margin for Bio-Rad Laboratories, Inc. (BIO)?
- The 5Y average gross margin for BIO stock is 54.60%.
- What is the 10Y average gross margin for Bio-Rad Laboratories, Inc. (BIO)?
- The 10Y average gross margin for BIO stock is 54.64%.
- What is the 15Y average gross margin for Bio-Rad Laboratories, Inc. (BIO)?
- The 15Y average gross margin for BIO stock is 55.00%.
- What is the 20Y average gross margin for Bio-Rad Laboratories, Inc. (BIO)?
- The 20Y average gross margin for BIO stock is 55.02%.
Bio-Rad Laboratories, Inc. Gross Margin History
| DATE | GROSS MARGIN |
|---|---|
| 2025-12-31 | 52.01% |
| 2024-12-31 | 53.73% |
| 2023-12-31 | 53.42% |
| 2022-12-31 | 55.93% |
| 2021-12-31 | 56.05% |
| 2020-12-31 | 56.48% |
| 2019-12-31 | 54.38% |
| 2018-12-31 | 53.46% |
| 2017-12-31 | 54.97% |
| 2016-12-31 | 55.03% |
| 2015-12-31 | 55.54% |
| 2014-12-31 | 54.18% |
| 2013-12-31 | 55.26% |
| 2012-12-31 | 56.11% |
| 2011-12-31 | 56.81% |
| 2010-12-31 | 56.64% |
| 2009-12-31 | 56.04% |
| 2008-12-31 | 54.55% |
| 2007-12-31 | 54.16% |
| 2006-12-31 | 55.93% |
| 2005-12-31 | 54.74% |
| 2004-12-31 | 55.97% |
| 2003-12-31 | 56.35% |
| 2002-12-31 | 57.07% |
| 2001-12-31 | 56.41% |
| 2000-12-31 | 58.66% |
| 1999-12-31 | 58.56% |
| 1998-12-31 | 58.93% |
| 1997-12-31 | 60.20% |
| 1996-12-31 | 60.82% |
Related Metrics
About Bio-Rad Laboratories, Inc.
Bio-Rad Laboratories, Inc., established in 1952 and headquartered in Hercules, California, operates as a global provider of life science research and clinical diagnostic products. Its operations span across the United States, Canada, Europe, Asia, and Latin America. The company is organized into two primary divisions: Life Science and Clinical Diagnostics. The Life Science division is responsible for developing, manufacturing, and commercializing a diverse array of reagents, equipment, and laboratory instruments. These products are crucial for various research methodologies, biopharmaceutical manufacturing processes, and food quality testing. This segment focuses on specialized areas within the life sciences, including proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. Its clientele encompasses academic institutions (such as universities and medical schools), industrial research organizations, government agencies, pharmaceutical companies, biotechnology firms, food producers, and food testing laboratories. In contrast, the Clinical Diagnostics division designs, produces, sells, and supports a comprehensive suite of test systems, informatics solutions, diagnostic kits, and specialized quality control products for clinical laboratories. This segment provides reagents, instruments, and software specifically tailored for particular niches within the in vitro diagnostics market. Its customer base includes reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. Beyond these core segments, Bio-Rad also offers systems and products designed to separate complex chemical and biological materials, as well as to identify, analyze, and purify their individual components. The company distributes its extensive product portfolio through a combination of its direct sales force and a network of third-party distributors, agents, brokers, and resellers.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Norman D. Schwartz